title: [The effects of individualized therapeutic programs on chronic hepatitis C and the influential factors of virological response].
abstract: OBJECTIVE
  To investigate the effect of individualized therapeutic programs with combination of interferon and ribavirin (RBV) in chronic hepatitis C (CHC) and study the influential factors of virological response rates.
  
  
  METHODS
  A total of 139 patients with CHC were enrolled and given the intensive treatment doses of interferon and RBV according to their basic clinical condition. At the treatment of 0, 4, 12, 24 weeks, the end of treatment and 24 weeks after treatment stop, the serum HCV RNA was determined. Timely adjustment to dosage and time periods was made according to the virological response to treatment, and the predictive value of rapid virological response (RVR) and complete early virological response (cEVR) for sustained virological response (SVR) were analyzed.
  
  
  RESULTS
  At the 4th week of treatment, the level of serum HCV RNA was monitored in 120 patients, and 84.2% (101/120) of patients obtained RVR; among them, 90.7% (88/97) obtained SVR. The virus load of patients obtained RVR at pretherapy was lower than that of patients didn't obtained RVR [(5.883 ± 1.246) lg copies/ml vs(6.502 ± 0.693) lg copies/ml, P = 0.034]. The RVR rate of initial treatment patients with PEG-IFNα-2a [87.8% (79/90)] was significantly higher than that of retreatment patients with PEG-IFNα-2a [65.0% (13/20)] (P = 0.031). At the 12th week of treatment, the level of serum HCV RNA was monitored in 132 patients, and 92.4% (122/132) of patients obtained cEVR; among them, 90.8% (108/119) obtained SVR. The SVR rate of patients obtained cEVR was significantly higher than that of patients didn't obtained cEVR (5/9) (P = 0.007). There was no significant difference between the cEVR rate of initial treatment patients [94.7% (90/95)] and retreatment patients [85% (17/20)] with PEG-IFNα-2a (P = 0.158).
  
  
  CONCLUSIONS
  cEVR was predictor of SVR. Individualized therapy can increase the obtaining probability of RVR, cEVR and SVR. Adjusting drug dose timely and extending treatment period of HCV RNA-negative based on virological response to treatment are important in CHC individualized therapy.
authors.affiliation: Department of Clinical Laboratory, the Affiliated Wenling Hospital of Wenzhou Medical College, Zhejiang 317500, China.
authors.forename: Mao-liang
authors.initials: ML
authors.lastname: Cheng
authors.forename: Jue
authors.initials: J
authors.lastname: Wang
authors.forename: Ai-ping
authors.initials: AP
authors.lastname: Zeng
authors.forename: Xue-feng
authors.initials: XF
authors.lastname: Liu
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000998:Antiviral Agents / Q000008:administration & dosage / Q000627:therapeutic use; D002648:Child; D005260:Female; D016174:Hepacivirus; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000821:virology*; D006801:Humans; D016898:Interferon-alpha / Q000008:administration & dosage / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D057285:Precision Medicine; D012367:RNA, Viral / Q000097:blood; D012254:Ribavirin / Q000008:administration & dosage / Q000627:therapeutic use; D016896:Treatment Outcome; D019562:Viral Load; D055815:Young Adult
chemical_list: D000998:Antiviral Agents; D016898:Interferon-alpha; D012367:RNA, Viral; D012254:Ribavirin